Parmaksiz S, Yüksel N, Karabas V L, Ozkan B, Demirci G, Caglar Y
Department of Ophthalmology, School of Medicine, Kocaeli University, Kocaeli, Turkey.
Eur J Ophthalmol. 2006 Jan-Feb;16(1):73-80.
To compare the intraocular pressure (IOP) lowering effect and safety of latanoprost, travoprost given every evening, and the fixed combination dorzolamide + timolol (DTFC) given twice daily in pseudoexfoliation glaucoma (PXG).
This randomized, prospective, investigator-masked study has been conducted with 50 PXG patients. Patients were assigned to one of three groups: travoprost 0.004%, fixed combination of dorzolamide 2%+timolol 0.5%, or latanoprost 0.005% for 6 months. At baseline and 0.5, 1, 2, 3, 4, 5, and 6 months of therapy, IOP (8 am, 10 am, 4 pm), blood pressures, and pulse rates were measured, and ophthalmologic examination was performed. The side effects were recorded at each visit.
Forty-two of the 50 patients initially enrolled completed this study. Withdrawn patients included one (latanoprost) for lack of efficacy, five (three travoprost, one latanoprost, one DTFC) for adverse events, and two (one latanoprost, one DTFC) for loss of follow-up. Each of the three drugs considerably reduced the IOP in PXG cases throughout the 6 months. Mean IOP reduction at 6 months was -9.3+/-2.9 mmHg in the travoprost group, -8.2+/-1.2 mmHg in the latanoprost group, and 11.5+/-3.3 mmHg in the DTFC group. Comparing the groups, DTFC is more effective than latanoprost and travoprost in lowering IOP (p<0.05). There was no difference between travoprost and latanoprost. The most common treatment-related adverse event was conjunctival hyperemia. Intensity of ocular hyperemia was greater in the travoprost group compared with the latanoprost and DTFC groups (p<0.05). There were no significant effects on systemic safety parameters.
The results demonstrated that DTFC is more effective in reducing IOP than latanoprost and travoprost. Latanoprost and travoprost had similar ocular hypotensive effects in patients with PXG. All three drugs were well tolerated; there were fewer ocular side effects attributable in the latanoprost group.
比较拉坦前列素、每晚使用的曲伏前列素以及每日两次使用的固定复方制剂多佐胺+噻吗洛尔（DTFC）在治疗假性剥脱性青光眼（PXG）时降低眼压（IOP）的效果及安全性。
对50例PXG患者进行了这项随机、前瞻性、研究者设盲的研究。患者被分为三组之一：0.004%曲伏前列素组、2%多佐胺+0.5%噻吗洛尔固定复方制剂组或0.005%拉坦前列素组，治疗6个月。在基线以及治疗的0.5、1、2、3、4、5和6个月时，测量眼压（上午8点、10点、下午4点）、血压和脉搏率，并进行眼科检查。每次就诊时记录副作用。
最初纳入的50例患者中有42例完成了本研究。退出研究的患者包括1例（拉坦前列素组）因疗效不佳、5例（3例曲伏前列素组、1例拉坦前列素组、1例DTFC组）因不良事件以及2例（1例拉坦前列素组、1例DTFC组）因失访。在整个6个月期间，三种药物中的每一种都能显著降低PXG患者的眼压。6个月时，曲伏前列素组平均眼压降低-9.3±2.9 mmHg，拉坦前列素组为-8.2±1.
